AI-discovered IL-17 inhibitor from Ascletis Pharma shows best-in-class potential
New phase I data suggests the oral small molecule ASC50 could help address immunology conditions such as psoriasis.
List view / Grid view
New phase I data suggests the oral small molecule ASC50 could help address immunology conditions such as psoriasis.
Despite some positive results from clinical trials for COVID-19 treatments, separate tests of the same therapies have not met primary endpoints.